Lupron Depot

Endometriosis, Iron Deficiency Anemia, Iron replacement therapy + 6 more

Treatment

20 Active Studies for Lupron Depot

What is Lupron Depot

Leuprolide

The Generic name of this drug

Treatment Summary

Leuprolide is a synthetic hormone-like drug used to reduce the levels of sex hormones in the body. It is a version of the natural hormone gonadotropin-releasing hormone (GnRH) and works by mimicking its effects on the body. Leuprolide is used to treat advanced prostate cancer, endometriosis, and early puberty. It is available as a daily subcutaneous injection under the name Lupron™ by Abbvie Endocrine Inc. and newer versions of the drug can be injected every six months. Leuprolide is the main treatment for these conditions.

Lupron

is the brand name

image of different drug pills on a surface

Lupron Depot Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Lupron

Leuprolide

1986

57

Effectiveness

How Lupron Depot Affects Patients

Leuprolide is a drug used to reduce the production of hormones like testosterone and estradiol. It is used to treat endometriosis, uterine leiomyomata, advanced prostate cancer, and central precocious puberty in children. When taking leuprolide, women should be aware of the risk of decreased bone mineral density and pregnancy complications. Men may experience flares of prostate cancer symptoms, as well as hyperglycemia, diabetes, and cardiovascular disease. In children, side effects may include convulsions and psychiatric symptoms. Patients with a history of depression should watch for recurrence of depressive symptoms.

How Lupron Depot works in the body

Leuprolide works by activating the release of hormones from the pituitary gland. This in turn leads to an increase in sex hormones, like testosterone and estrogen. After a few weeks of use, the hormones stop being released and the effects of leuprolide are reversed.

When to interrupt dosage

The endorsed dose of Lupron Depot is contingent upon the diagnosed condition, including Anger Management Therapy, Central Precocious Puberty (CPP) and Uterine Fibroids. The dosage is dependent on the method of delivery (e.g. Intramuscular or Intramuscular; Topical) specified in the table hereunder.

Condition

Dosage

Administration

Endometriosis

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Palliative Treatment

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Puberty, Precocious

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Uterine Fibroids

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

symptom recurrence

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Prostatic Neoplasms

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

confirmed by clinical features

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Iron Deficiency Anemia

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Iron replacement therapy

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Warnings

Lupron Depot Contraindications

Condition

Risk Level

Notes

Vaginal Hemorrhage

Do Not Combine

Pregnant Women

Do Not Combine

Metrorrhagia

Do Not Combine

Breast Neoplasms

Do Not Combine

Liver Neoplasms

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Leuprolide may interact with Pulse Frequency

There are 20 known major drug interactions with Lupron Depot.

Common Lupron Depot Drug Interactions

Drug Name

Risk Level

Description

Amiodarone

Major

The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amiodarone.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Artemether.

Asenapine

Major

The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Asenapine.

Lupron Depot Toxicity & Overdose Risk

Leuprolide has been found to be very safe, with minimal side effects. Even when taken at high doses of up to 20mg per day for two years, prostate cancer patients did not experience any additional adverse effects compared to those taking a much lower dose of 1mg per day.

image of a doctor in a lab doing drug, clinical research

Lupron Depot Novel Uses: Which Conditions Have a Clinical Trial Featuring Lupron Depot?

144 active trials are currently in progress to assess the efficacy of Lupron Depot for alleviating symptom recurrence, Uterine Fibroids and Iron Deficiency Anemia.

Condition

Clinical Trials

Trial Phases

Iron Deficiency Anemia

20 Actively Recruiting

Phase 3, Not Applicable, Phase 2, Phase 1, Phase 4

symptom recurrence

0 Actively Recruiting

Puberty, Precocious

1 Actively Recruiting

Phase 3

Endometriosis

27 Actively Recruiting

Early Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4

Prostatic Neoplasms

0 Actively Recruiting

confirmed by clinical features

0 Actively Recruiting

Palliative Treatment

1 Actively Recruiting

Phase 3

Iron replacement therapy

0 Actively Recruiting

Uterine Fibroids

13 Actively Recruiting

Phase 2, Early Phase 1, Phase 3, Not Applicable, Phase 4

Lupron Depot Reviews: What are patients saying about Lupron Depot?

4.7

Patient Review

7/10/2021

Lupron Depot for Advanced Form of Prostate Cancer

The 3-month lupron injection was a success in my case. It brought my testosterone level from 840 to 11 within three weeks! However, there are side effects that come with it, including: 1) lack of sexual desire and performance; 2) hot flashes; 3) fatigue; and 4) low red blood cell count (anemia). Despite all this, the drug is still effective in fighting prostate cancer.

4.7

Patient Review

7/10/2021

Lupron Depot for Advanced Form of Prostate Cancer

The 3 month lupron injection was very effective in lowering my testosterone levels. However, it did come with some nasty side-effects like hot flashes and fatigue.

4.7

Patient Review

7/10/2021

Lupron Depot for Advanced Form of Prostate Cancer

Lupron is a pretty effective drug, but it's not without its drawbacks. I experienced decreased sexual desire and performance, hot flashes, fatigue, and low red blood cell count (anemia). So while it was successful in treating my prostate cancer, it wasn't exactly a fun experience.

4.3

Patient Review

7/5/2022

Lupron Depot for Advanced Form of Prostate Cancer

I've been on Lupron for three years now, taking it every three months to keep my prostate cancer at bay. It does lower my PSA and testosterone levels as well as slowing the cancer's growth, but the side effects are pretty harsh. I get hot flashes all day long, every day, and they range in intensity. They make it impossible to get a good night's sleep, which is really tough. I haven't found any medication that helps much with them; it's just something I have to deal with.

4.3

Patient Review

7/5/2022

Lupron Depot for Advanced Form of Prostate Cancer

Lupron is effective at its job, but the side effects are harsh. I get hot flashes constantly throughout the day and they make it impossible to get a good night's sleep. I haven't found any medication that really helps with this symptom.

4.3

Patient Review

7/5/2022

Lupron Depot for Advanced Form of Prostate Cancer

Lupron is an effective treatment for reacurring prostate cancer, slowing the growth of the cancer and lowering PSA levels. However, the side effects can be difficult to deal with. I suffer from constant hot flashes which make it impossible to get a good night's sleep. I haven't found any medication that helps much with this side effect, so it's a trade-off between dealing with the cancer and dealing with the side effects.

3.7

Patient Review

1/14/2014

Lupron Depot for Advanced Form of Prostate Cancer

My blood pressure increased while taking this medication, and there were some side effects that weren't explained to me ahead of time. All things considered, I would still take it again if given the choice.

3.7

Patient Review

1/14/2014

Lupron Depot for Advanced Form of Prostate Cancer

Overall, this treatment did help me. However, my blood pressure increased while taking it and I experienced some side effects that were not explained to me beforehand.

3.7

Patient Review

1/14/2014

Lupron Depot for Advanced Form of Prostate Cancer

Although my blood pressure went up and I experienced some unexpected side effects, I would still choose to take this medication again.

3

Patient Review

3/6/2014

Lupron Depot for Advanced Form of Prostate Cancer

I've been using this treatment for a month now, and it's helped me a lot.

3

Patient Review

3/6/2014

Lupron Depot for Advanced Form of Prostate Cancer

I've been using this treatment for about a month now.

3

Patient Review

3/6/2014

Lupron Depot for Advanced Form of Prostate Cancer

I tried this treatment for a month and saw some results.

2.3

Patient Review

3/19/2014

Lupron Depot for Advanced Form of Prostate Cancer

I've been on this medication for 15 months, and it has helped me during my radiation treatments for prostate cancer. However, the side effects have been very challenging to deal with. These include: continual fatigue, hot flashes/sweats, memory challenges, swollen calves/feet, swollen hands, joint pain/aches in legs & hands, body hair loss, numbing down right arm & hand. Zero libido. Mild pain sensations over lower body mostly during sleep time. Restless sleep, therefore fatigue during daytime.

2.3

Patient Review

3/19/2014

Lupron Depot for Advanced Form of Prostate Cancer

I've been on this medication for 15 months, and it's been a real challenge. The side effects are never-ending fatigue, hot flashes and sweats, memory problems, swollen calves and feet, swollen hands, joint pain in legs and hands, body hair loss, numbness in right arm and hand, zero libido. While the benefits have been good, the side effects are really tough to deal with.

2.3

Patient Review

3/19/2014

Lupron Depot for Advanced Form of Prostate Cancer

I've been on this medication for 15 months now, and it has helped me through my prostate cancer radiation treatments. However, the side effects have been very difficult to deal with. I'm constantly tired, hot flashes/sweats, memory challenges, swollen calves/feet, swollen hands, joint pain/aches in legs & hands, body hair loss, numbing down right arm & hand. Zero libido. Mild pain sensations over lower body mostly during sleep time. Restless sleep, therefore fatigue during daytime.

1

Patient Review

3/21/2014

Lupron Depot for Puberty at an Earlier Age than would be expected

My daughter started taking this medication when she was seven years old. Within a year, she had gained 30 pounds, grown two inches, gone up three shoe sizes, developed acne, and experienced severe depression and anti-social behavior at school. The side effects of this medication are not worth the benefits.

1

Patient Review

3/21/2014

Lupron Depot for Puberty at an Earlier Age than would be expected

My daughter started this medication at the age of 7 yearsold. She was 5-2", wore a size 7 shoe, and 125 lbs. 1year later months later, she has severe depression, anti-social behavior at school, sleep walks and has full conversations in her sleep, lethargic and we have to force her to play sports, she has gained 30 lbs in a year even though she is consisently in the gym and non-stop sports (by force), grown 2 inches, 3 shoe sizes and has full acne. The side effects are really bad compared to any potential benefits.

1

Patient Review

3/21/2014

Lupron Depot for Puberty at an Earlier Age than would be expected

We started our daughter on this medication when she was seven years old. She was five-two", wore a size seven shoe, and weighed 125 pounds. One year later, she developed severe depression, anti-social behavior at school, sleep walking, and conversations in her sleep. Additionally, she became lethargic and we had to force her to play sports. In the span of one year, she gained 30 pounds despite being constantly active, grew two inches, and went up three shoe sizes. The side effects of this medication are not worth it.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about lupron depot

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does depot Lupron do?

"The drug Lupron Depot is used to manage endometriosis, alleviating pain and reducing the presence of endometriotic lesions."

Answered by AI

Is Lupron Depot a chemo drug?

"Lupron is a chemo agent that is used to decrease the amount of certain hormones in the body to treat the symptoms associated with prostate cancer."

Answered by AI

Where is depot Lupron injected?

"Lupron Depot is a medication that is injected into a muscle once a month, or every three, four, or six months for the treatment of prostate cancer. Depot formulations are designed to release medication into the body over a certain period of time."

Answered by AI

What are the long term side effects of Lupron Depot?

"A tumor flare with prostate cancer may cause your endometriosis symptoms to worsen before they improve. High blood sugar levels may lead to type 2 diabetes. Taking Lupron Depot for a long period of time may cause a loss of bone density."

Answered by AI

Clinical Trials for Lupron Depot

Image of University Hospitals Cleveland Medical Center in Cleveland, United States.

Ketamine for Pelvic Pain

18 - 89
Female
Cleveland, OH

The purpose of this research study is to see if ketamine infusion during surgery can decrease pain after surgery. Ketamine is a medication commonly used as part of anesthesia during surgery and is approved by the US FDA. Patients will be randomized to either receive standard anesthesia with OR without ketamine. The surgical procedure will be the same regardless of which group patients are randomized to. After surgery, patients will be asked to rate their pain in the post-operative observation unit and at their two-week post-operative visit. No additional visits are required for participation in this study. The investigators estimate the surveys will take approximately 10 minutes to complete.

Phase 4
Waitlist Available

University Hospitals Cleveland Medical Center

Morgan Cheeks, MD

Have you considered Lupron Depot clinical trials?

We made a collection of clinical trials featuring Lupron Depot, we think they might fit your search criteria.
Go to Trials
Image of Hospital of the University of Pennsylvania in Philadelphia, United States.

Educational Video for Uterine Fibroids

18 - 55
All Sexes
Philadelphia, PA

Uterine fibroids are a common condition that can cause heavy and/or painful menstrual bleeding. There are many treatment options, but they vary in efficacy, side effects, short-term recovery and long-term implications for future fertility. Patients can have difficulty deciding between these options. In this study, the investigators will randomly assign patients seeking treatment for fibroids to receive an educational video on fibroids and their treatment, versus usual care (no video). The investigators will assess their decisional conflict with and without exposure to the video using a validated survey to see if exposure to the educational video helps them make decisions.

Recruiting
Has No Placebo

Hospital of the University of Pennsylvania

Anuja Dokras, MD

Image of University Health Network (UHN) in Toronto, Canada.

Mitapivat for Anemia

18+
All Sexes
Toronto, Canada

This is a prospective exploratory phase 2 study designed to evaluate the safety and efficacy of mitapivat in RBC membranopathies and CDAII, a rare sub type of anemia. Nine patients from Princess Margaret who are diagnosed with CDAII will be enrolled to the study. Patients will be in the trial for 57 weeks treatment weeks and a safety follow up week after 30 days from last dose. First 8 weeks will be dose escalating period followed by 48 weeks of fixed dose period. 57th week will be dose tapering week. Data collected from Princes Margaret will be incorporated to the main study conducted in EU for analysis. Overall, approximately 25 patients are expected to be enrolled: Approximately 16 patients at sites in the EU and approximately 9 patients in Canada.

Phase 2
Recruiting

University Health Network (UHN)

Agios Pharmaceuticals, Inc.

Have you considered Lupron Depot clinical trials?

We made a collection of clinical trials featuring Lupron Depot, we think they might fit your search criteria.
Go to Trials
Image of Alethios, Inc. in San Francisco, United States.

NettleEndo for Endometriosis

22 - 45
Female
San Francisco, CA

The goal of this clinical trial is to learn if a wearable brain stimulation device called NettleEndo can reduce chronic pelvic pain and improve wellbeing in women with endometriosis. The study also aims to assess the safety and usability of the device when used at home over several months. The main questions it aims to answer are: 1. Does at-home transcranial direct current stimulation (tDCS) reduce daily pain intensity in women with endometriosis? 2. Does the device also improve mood and sleep quality? Researchers will compare two groups-one receiving active brain stimulation and one receiving a sham (placebo) stimulation-to see if the active device provides greater improvements in symptoms. Participants will: 1. Use the NettleEndo device at home for 20 minutes per session, five times per week for 12 weeks 2. Be randomly assigned to receive either real or sham stimulation through the device 3. Complete daily and weekly symptom ratings through a mobile app 4. Be followed for 90 days after completing the intervention to monitor longer-term effects All activities are completed remotely using a smartphone app. Participants can contact the study team with questions at any time. The study is double-blind, meaning neither participants nor the researchers assessing outcomes will know who received active or sham treatment until the end of the trial.

Recruiting
Online Trial

Alethios, Inc.

Nirav Shah, MD, MPH

Samphire Group, Inc.

Image of Baylor College of Medicine in Hosuton, United States.

Dronabinol for Endometriosis

18 - 64
Female
Hosuton, TX

This exploratory, proof-of-concept study is a double-blind (participants and investigators will be blinded), placebo-controlled, randomized, two-arm clinical trial of Marinol \[dronabinol, synthetic Δ9-tetrahydrocannabinol (THC)\] for e endometriosis-associated chronic pelvic pain (endo-CPP) with a 2:1 allocation ratio. Up to 75 subjects will be enrolled in this pilot study and randomized to receive doses of THC (up to 30 mg/day), orally, over 8 weeks. This study will be conducted at a single site; it does not include any stratifications, and there is no interim analysis planned. Notably, the goal is to determine whether there is enough evidence of the safety of THC to support the development of later-phase clinical trials. Thus, detailed developmental plans are contingent on the outcomes of this study.

Phase 2
Waitlist Available

Baylor College of Medicine (+1 Sites)

Christopher Verrico, PhD in Pharmacology

Image of Weill Cornell Medical College in New York, United States.

Luspatercept for Clonal Cytopenia

18+
All Sexes
New York, NY

The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include: * How many patients experience improvements in their low blood counts (red cells, platelets, or white cells) within 24 weeks, based on specific criteria for blood conditions like myelodysplastic syndromes (MDS)? * How long these improvements last before the condition worsens or changes. * The percentage of participants showing improvements at 12, 24, and 48 weeks. * How long it takes for the condition to progress to more severe diseases like myeloid disorders. * How long red blood cell responses last and how quickly these responses are seen. * The average change in hemoglobin levels over 24 weeks. * How many patients need blood transfusions during the study and how soon transfusions are required. * Changes in participants' well-being and energy levels based on a standardized questionnaire. * Monitoring for any side effects, including progression to MDS or leukemia, heart-related issues, or sudden increases in hemoglobin. Participants will: * Receive luspatercept as an injection every three weeks. * Visit the clinic every three weeks for treatment and monitoring.

Phase 2
Recruiting

Weill Cornell Medical College

Pinkal Desai, MD

Bristol-Myers Squibb

Have you considered Lupron Depot clinical trials?

We made a collection of clinical trials featuring Lupron Depot, we think they might fit your search criteria.
Go to Trials